Viridian Therapeutics, Inc.\DE SEC filings VRDN
Viridian Therapeutics, Inc.\DE has 817 filings in SEC EDGAR's recent list, going back to Nov 12, 2013. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | Jun 2, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 20, 2025 |
| DEFA14A | Additional proxy material | Jun 10, 2024 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 17, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Jun 4, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Apr 30, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2021 | Apr 14, 2021 |
| DEF 14A | Proxy statement | Dec 14, 2020 | Dec 31, 2020 |
| PRE 14A | Preliminary proxy statement | Nov 20, 2020 | Nov 20, 2020 |
| DEFA14A | Additional proxy material | Apr 10, 2020 | — |
| DEF 14A | Proxy statement | Apr 10, 2020 | Apr 10, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2020 | Mar 27, 2020 |
| DEFA14A | Additional proxy material | May 3, 2019 | — |
| DEF 14A | Proxy statement | May 3, 2019 | May 3, 2019 |
| DEFA14A | Additional proxy material | May 15, 2018 | — |
| DEF 14A | Proxy statement | May 15, 2018 | Jun 27, 2018 |
| DEFA14A | Additional proxy material | May 15, 2017 | — |
| DEF 14A | Proxy statement | May 15, 2017 | Jun 28, 2017 |
| DEF 14A | Proxy statement | May 9, 2016 | Jun 15, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2016 | Jun 15, 2016 |
| DEF 14A | Proxy statement | May 26, 2015 | Jun 18, 2015 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.